Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EC-401
- Development stage
- Preclinical
- Lead developer
- Eclipse Life Sciences
- Modality
- Small Molecules
- Administration
- Ophthalmic, Intravitreal
01
Overview
EC-401 is an experimental, extended-release intravitreal therapeutic being developed by Eclipse Life Sciences for the treatment of retinal diseases. It is designed to provide both anti-inflammatory and anti-fibrotic activity, specifically targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) that is resistant to standard anti-VEGF monotherapy. The designation 'CaM-I' suggests that the drug functions as a calmodulin inhibitor, a mechanism intended to address the underlying inflammatory and fibrotic processes in the retina. By utilizing an extended-release formulation for intravitreal administration, EC-401 aims to provide sustained therapeutic levels of the drug while reducing the frequency of ocular injections required for patients.
Beyond the preview
Go deeper on EC-401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EC-401.